Biotechnology company · INSM

Insmed
clinical trial
pipeline

Registry checked

Published

Treprostinil Palmitil Inhalation Powder is linked to 5 distinct active studies, with 1 Phase 1, 4 Phase 3. Treprostinil Palmitil is linked to 1 distinct active study, with 1 Phase 3.

Phase 3 study NCT05649748 in Pulmonary Arterial Hypertension lists estimated primary completion on 31 December 2026. These are registry estimates of primary completion, not confirmed results announcements or overall study completion.

Active trial mix

Lead-sponsor scope

8active trials
as lead sponsor
  • Phase 13
  • Phase 20
  • Phase 35
  • Phase 40
  • Phase not recorded0

One highest explicitly recorded phase per active trial. Combined phases use the highest phase. Phase not recorded is shown separately.

Change history

Follow the changes behind the company’s clinical programme.

02 Oct 2026 – 31 Oct 2026 · UTC

Recorded changes

00 trials30 completed days

No eligible observations recorded in this period.

Recruitment statusPrimary completionEnrolmentFirst observedOther

Verified live registry-derived observations in completed UTC days. Recorded dates are observation dates, not necessarily registry amendment dates. Zero means no eligible observations recorded, not daily monitoring of every trial.

0 archive observations and 0 unverified observations excluded.

View exact daily values and type totals
Recorded observations in completed UTC days
Date (UTC)Recruitment statusPrimary completionEnrolmentFirst observedOtherTotalAffected trials
2026-10-020000000
2026-10-030000000
2026-10-040000000
2026-10-050000000
2026-10-060000000
2026-10-070000000
2026-10-080000000
2026-10-090000000
2026-10-100000000
2026-10-110000000
2026-10-120000000
2026-10-130000000
2026-10-140000000
2026-10-150000000
2026-10-160000000
2026-10-170000000
2026-10-180000000
2026-10-190000000
2026-10-200000000
2026-10-210000000
2026-10-220000000
2026-10-230000000
2026-10-240000000
2026-10-250000000
2026-10-260000000
2026-10-270000000
2026-10-280000000
2026-10-290000000
2026-10-300000000
2026-10-310000000
Type totals0000000 distinct

02 / Drugs & programmes

Explore the pipeline

3 selected programmes

Choose a drug to open its record in the tracker. Sign in to continue.

Treprostinil Palmitil Inhalation Powder

Canonical investigational asset

5
Active trials
4
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 11
  • Phase 20
  • Phase 34
  • Phase 40
  • Phase not recorded0
Studied condition
Hepatic Impairment · Interstitial Lung Disease · Progressive Pulmonary Fibrosis
Next primary completion
Not reported
Open drug

Treprostinil Palmitil

Canonical investigational asset

1
Active trials
0
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 20
  • Phase 31
  • Phase 40
  • Phase not recorded0
Studied condition
Pulmonary Arterial Hypertension
Next primary completion
31 December 2026 · estimated
Open drug

Brensocatib

BRINSUPRI

1
Active trials
0
Recruiting trials
Trial phases
Highest: Phase 1
  • Phase 11
  • Phase 20
  • Phase 30
  • Phase 40
  • Phase not recorded0
Studied condition
Healthy Volunteers
Next primary completion
Not reported
Open drug

7 of 8 active trials have accepted investigational programme links. Trial context does not establish ownership or complete drug coverage.

3 selected programmes · accepted investigational links cover 7 of 8 active trials · brand names checked where available.

Accepted links do not establish complete intervention mapping or ownership. Programme populations overlap.

Up to six canonical assets identified through accepted investigational links in active trials. Counts describe this trial context and do not establish ownership or a complete corporate drug portfolio. Opening a record requires sign-in and does not start tracking.

03 / Clinical trial timeline

Insmed trials in progress

Registry start → study completion

◇ Recorded observation│ Primary completion milestoneHatched ends retain month / year uncertaintyHover, focus or tap an observation
Trial / programme
4 selected Phase 3 / 2 trials
2021202220232024202520262027202820292030
An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)
Treprostinil Palmitil

NCT05649748

Phase 3 · Active, not recruiting

Trial source and qualifications

An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)

Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 2 inspected observations were not displayed.

2 candidate observations · 0 shown · 0 recorded after primary completion · 2 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

ClinicalTrials.gov source

2 inspected observations omitted. At most three verified observations are shown, not full history.

    Start: 07 Mar 2023 · actual
    Primary completion: 31 Dec 2026 · estimated
    Study completion: 31 Dec 2026 · estimated

    2021202220232024202520262027202820292030
    PALM-PAH
    Treprostinil Palmitil Inhalation Powder

    NCT07481981

    Phase 3 · Recruiting

    Trial source and qualifications

    A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)

    Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 1 inspected observations were not displayed.

    1 candidate observations · 0 shown · 0 recorded after primary completion · 1 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

    ClinicalTrials.gov source

    1 inspected observations omitted. At most three verified observations are shown, not full history.

      Start: 21 Jul 2026 · actual
      Primary completion: 28 Dec 2028 · estimated
      Study completion: 28 Jan 2029 · estimated

      2021202220232024202520262027202820292030
      PALM-ILD
      Treprostinil Palmitil Inhalation Powder

      NCT07179380

      Phase 3 · Recruiting

      Trial source and qualifications

      Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

      Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 1 inspected observations were not displayed.

      1 candidate observations · 0 shown · 0 recorded after primary completion · 1 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

      ClinicalTrials.gov source

      1 inspected observations omitted. At most three verified observations are shown, not full history.

        Start: 07 Jan 2026 · actual
        Primary completion: 30 Dec 2028 · estimated
        Study completion: 30 Dec 2028 · estimated

        2021202220232024202520262027202820292030
        PALM-PPF
        Treprostinil Palmitil Inhalation Powder

        NCT07805785

        Phase 3 · Not yet recruiting

        Trial source and qualifications

        A Study to Assess the Efficacy and Safety of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Progressive Pulmonary Fibrosis (PPF)

        Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history.

        0 candidate observations · 0 shown · 0 recorded after primary completion · 0 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

        ClinicalTrials.gov source

        No eligible observations recorded in the inspected period.

          Start: 01 Dec 2026 · estimated
          Primary completion: 31 Aug 2030 · estimated
          Study completion: 31 Aug 2030 · estimated

          2021202220232024202520262027202820292030

          Up to six active Phase 2/3 trials with upcoming estimated primary-completion intervals, ordered by nearest interval, highest phase and NCT. Historical dates never pad this selection. Ten calendar years are shown. Dates retain registry precision and independent date types.

          4 selected of 4 eligible trials · 0 without supported dates · 0 omitted for contradictory chronology. Excluded: 0 actual primary completions, 0 untyped primary completions, 0 past estimates, 1 outside the horizon, 0 contradictory dates.

          04 / Therapeutic focus

          Where the activity is

          5

          active trials in Respiratory

          Primary therapeutic groups are indexed enrichment. Unmapped trials and healthy volunteers remain in the active-trial denominator.

          Active trials by primary therapeutic area

          • Respiratory5 trials
          • Gastroenterology & Hepatology1 trials
          • Unmapped0 trials
          • Healthy volunteers2 trials

          Each active trial counts once. Full bar equals all active trials in this lead-sponsor scope. This grouping does not describe commercial strategy.

          06 / Related companies

          All companies
          A

          AstraZeneca

          Shared indexed programme context · 1 selected asset

          Based on the selected programmes and indexed lead-sponsor records, not a complete ranking or a competitive/ownership assessment.

          Sources, scope and methodology

          ClinicalTrials.gov lead-sponsor scope

          Canonical current-owner attribution covers 50 distinct NCT records attributed through the canonical sponsor map. Included canonical entities: Insmed Incorporated. Phrases retrieve candidates only, then verbatim lead-sponsor attribution determines inclusion.

          ClinicalTrials.gov

          Attribution coverage

          50 distinct registry candidates produced 50 accepted studies. 0 mapped to other owners, 0 lacked a canonical mapping and 0 fell outside an operating subset. Accepted mappings include 0 unverified, 0 identity-only and 0 device-tagged trial memberships. Mapping flags describe evidence quality, not a separate ownership authority.

          Indexed enrichment

          48 scoped records have indexed enrichment and 2 do not. Missing enrichment does not remove a trial from cohort counts.

          Scope observation

          The successful attribution check completed at 2026-11-01T02:49:08.260Z. This is a dated canonical-attribution snapshot. Static pages normally regenerate after 24 hours, but cached HTML can outlive that interval when regeneration fails. Map changes affect the next successful regeneration. This timestamp is separate from individual registry-update dates. Snapshot ed28c6d5fcc95dd7a83ace8328849f8f4e29470d18018cff549f38bd8e29dd95.

          Active means recruiting, not yet recruiting, active not recruiting or enrolling by invitation. Recruiting counts recruiting only. Trial counts describe lead sponsorship under the published canonical-attribution policy. Identified programmes and therapeutic groups depend on available enrichment. Drug, device and other clinical studies may be included. This is the mapped company scope, not an exhaustive corporate trial census.

          Dated canonical-attribution snapshot: 50 mapped lead-sponsored clinical studies across all statuses. 48 have indexed enrichment, 2 do not. Drug, device and other studies may be represented. Sponsor tags do not classify trial interventions. This is the mapped company scope, not an exhaustive corporate trial census. Recorded changes may reflect observation or archive ingestion rather than a new registry amendment.

          Keep following
          what matters.

          Choose the drugs, companies or disease areas you follow. Bring trial changes and upcoming readouts into one watch.

          Build your watch

          Choose what to track in the watch builder.